Abstract
A large number of studies have implicated activation of innate immune mechanisms in the pathogenesis of chronic obstructive pulmonary disease (COPD). Accumulation of inflammatory cells, chemokines and pro-inflammatory cytokines is a hallmark of activation of these mechanisms, but only a few studies have focussed on antimicrobial peptides in COPD. These peptides are a central component of innate immunity, and airway epithelial cells and neutrophils in the lung are the main cellular sources. In addition to their direct antimicrobial action, antimicrobial peptides have been shown to display a variety of activities that may implicate them in the pathogenesis of COPD. This is based on the observation that they not only contribute to defense against respiratory pathogens that have been associated with COPD, but may also contribute to the influx of inflammatory cells, activation of adaptive immunity and epithelial remodeling. The aim of this review is to provide an update on the basic biology of antimicrobial peptides in the lung, with a focus on their putative role in COPD. In addition, the implication of this knowledge for future treatment of COPD is discussed.
Keywords: COPD, antimicrobial peptide, defensin, cathelicidin, innate immunity, host defense, drug development
Current Drug Targets
Title: Antimicrobial Peptides in COPD - Basic Biology and Therapeutic Applications
Volume: 7 Issue: 6
Author(s): Robert Bals and Pieter S. Hiemstra
Affiliation:
Keywords: COPD, antimicrobial peptide, defensin, cathelicidin, innate immunity, host defense, drug development
Abstract: A large number of studies have implicated activation of innate immune mechanisms in the pathogenesis of chronic obstructive pulmonary disease (COPD). Accumulation of inflammatory cells, chemokines and pro-inflammatory cytokines is a hallmark of activation of these mechanisms, but only a few studies have focussed on antimicrobial peptides in COPD. These peptides are a central component of innate immunity, and airway epithelial cells and neutrophils in the lung are the main cellular sources. In addition to their direct antimicrobial action, antimicrobial peptides have been shown to display a variety of activities that may implicate them in the pathogenesis of COPD. This is based on the observation that they not only contribute to defense against respiratory pathogens that have been associated with COPD, but may also contribute to the influx of inflammatory cells, activation of adaptive immunity and epithelial remodeling. The aim of this review is to provide an update on the basic biology of antimicrobial peptides in the lung, with a focus on their putative role in COPD. In addition, the implication of this knowledge for future treatment of COPD is discussed.
Export Options
About this article
Cite this article as:
Bals Robert and Hiemstra S. Pieter, Antimicrobial Peptides in COPD - Basic Biology and Therapeutic Applications, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435227
DOI https://dx.doi.org/10.2174/138945006777435227 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer
Current Medicinal Chemistry Liposomal Targeting of Angiogenic Vasculature
Current Drug Delivery Treatment Modalities for Hepatocellular Carcinoma
Current Cancer Drug Targets Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells
Anti-Cancer Agents in Medicinal Chemistry In Silico Modeling of P450 Substrates, Inhibitors, Activators, and Inducers
Combinatorial Chemistry & High Throughput Screening The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease
Current Drug Targets - CNS & Neurological Disorders Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre and Faustino Mollinedo)]
Recent Patents on Anti-Cancer Drug Discovery Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats
Current Molecular Pharmacology A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2
Current Drug Targets Glioma Targeting and Anti-glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles
Current Pharmaceutical Biotechnology Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Effects of Pulmonary Blood Flow on Respiratory Mechanics: Measurements by the End-Inflation Occlusion Method in Healthy Rats After Acute Blood Volume Expansion
Current Respiratory Medicine Reviews Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Exosomes: Natural Carriers for siRNA Delivery
Current Pharmaceutical Design RNA Interference as A Gene-Specific Approach for Molecular Medicine
Current Medicinal Chemistry